Mogrify reports preclinical evidence of retinal regeneration using in vivo cell reprogramming

Mogrify demonstrates potential of retinal reprogramming therapy

Cambridge-based regenerative medicine company Mogrify Limited has announced positive preclinical proof-of-concept data for its lead retinal regeneration programme, demonstrating the potential of its technology to preserve and restore visual function.

The findings, generated in a rodent model of induced retinal degeneration, showed statistically significant improvements across multiple functional endpoints.

Mogrify's approach uses transcription factor-mediated direct reprogramming to convert Müller glial cells into functional photoreceptors within the retina. Photoreceptors are light-sensitive cells responsible for detecting light and transmitting visual signals to the brain. Their loss is a key feature of several degenerative retinal conditions.

By converting existing retinal cells into photoreceptors, the company aims to address the underlying cell loss associated with retinal degeneration, potentially offering an alternative to approaches based on cell transplantation.

AAV delivery and transcription factors underpin the approach

The preclinical study used adeno-associated virus (AAV) delivery to introduce combinations of transcription factors identified through Mogrify's proprietary platform.

The platform combines next-generation sequencing with human gene regulatory network analysis to identify transcription factor combinations capable of controlling cell fate and enabling direct conversion between different cell types.

According to the company, the study demonstrated both preservation and restoration of visual function across multiple dosing formats.

Dr Jonathan Appleby, Chief Scientific Officer at Mogrify, said: "We are thrilled to have generated statistically robust evidence that AAV delivery of MOGRIFY-identified transcription factor combinations can both protect against and reverse vision loss in a preclinical model of retinal degeneration. Demonstrated across several dosing formats and multiple functional endpoints, these findings represent an important step towards the development of a fundamentally novel and gene-agnostic approach to treating retinal disease."

Mogrify explores partnerships ahead of clinical development

Mogrify is now looking to advance the programme towards first-in-human studies, with Dr Appleby leading development. The company is actively exploring licensing and investment opportunities to support the next stages.

Joe Foster, Chief Executive Officer at Mogrify, said:

Findings to be presented at FLORetina-ICOOR 2026

The data will be presented at the FLORetina-ICOOR 2026 Congress, taking place from 3–6 December, in a session titled Delivery of a selected combination of transcription factors can improve visual function in a preclinical model of retinal degeneration.

The presentation will take place on Thursday 3 December, between 12:00 and 13:00, as part of the IRD 1 – Natural History, Endpoints & Therapies track. The findings will also feature in The Dolphin Tank, EYENOVATE's ophthalmology and vision science innovation showcase.